MXRA7

Summary

MXRA7 (matrix remodeling associated 7, HGNC:7541) is a protein-coding gene on chromosome 17q25.1, encoding Matrix-remodeling-associated protein 7 (P84157). It is a selective cancer dependency (DepMap: 29.3% of cell lines).

Located in endoplasmic reticulum.

Source: NCBI Gene 439921 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 46 total
• Cancer dependency (DepMap): dependent in 29.3% of screened cell lines
• MANE Select transcript: NM_198530

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7541
Approved symbol	MXRA7
Name	matrix remodeling associated 7
Location	17q25.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ46603, TMAP1, PS1TP1
Ensembl gene	ENSG00000182534
Ensembl biotype	protein_coding
Entrez	439921

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000355797, ENST00000375036, ENST00000449428, ENST00000585519, ENST00000588114, ENST00000589082, ENST00000592148

RefSeq mRNA: 7 — MANE Select: NM_198530 NM_001008528, NM_001008529, NM_001363769, NM_001387276, NM_001387277, NM_001387278, NM_198530

CCDS: CCDS32745, CCDS32746, CCDS45786, CCDS86640

Canonical transcript exons

ENST00000449428 — 4 exons

Exon	Start	End
ENSE00002777776	76710605	76710965
ENSE00003558697	76679566	76680879
ENSE00003597696	76685072	76685165
ENSE00003691720	76688113	76688176

Expression profiles

Bgee: expression breadth ubiquitous, 294 present calls, max score 99.80.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.3776 / max 118.6234, expressed in 1615 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
168269	15.9350	1599
168266	0.5139	285
168270	0.4916	268
168268	0.4372	222

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
saphenous vein	UBERON:0007318	99.80	gold quality
decidua	UBERON:0002450	99.71	gold quality
pigmented layer of retina	UBERON:0001782	99.70	gold quality
urethra	UBERON:0000057	99.61	gold quality
vena cava	UBERON:0004087	99.57	gold quality
type B pancreatic cell	CL:0000169	99.56	gold quality
seminal vesicle	UBERON:0000998	99.52	gold quality
choroid plexus epithelium	UBERON:0003911	99.49	gold quality
blood vessel layer	UBERON:0004797	99.49	gold quality
adult organism	UBERON:0007023	99.46	gold quality
cranial nerve II	UBERON:0000941	99.35	gold quality
skin of hip	UBERON:0001554	99.35	gold quality
synovial joint	UBERON:0002217	99.35	gold quality
lateral globus pallidus	UBERON:0002476	99.35	gold quality
heart right ventricle	UBERON:0002080	99.33	gold quality
olfactory bulb	UBERON:0002264	99.33	gold quality
right coronary artery	UBERON:0001625	99.31	gold quality
smooth muscle tissue	UBERON:0001135	99.30	gold quality
right atrium auricular region	UBERON:0006631	99.30	gold quality
mucosa of stomach	UBERON:0001199	99.28	gold quality
apex of heart	UBERON:0002098	99.27	gold quality
adrenal tissue	UBERON:0018303	99.27	gold quality
popliteal artery	UBERON:0002250	99.24	gold quality
tibial artery	UBERON:0007610	99.24	gold quality
aorta	UBERON:0000947	99.23	gold quality
ascending aorta	UBERON:0001496	99.23	gold quality
myometrium	UBERON:0001296	99.22	gold quality
thoracic aorta	UBERON:0001515	99.22	gold quality
calcaneal tendon	UBERON:0003701	99.22	gold quality
cauda epididymis	UBERON:0004360	99.20	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7037	yes	473.67
E-ANND-3	yes	15.60

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

42 targeting MXRA7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-4804-3P	99.65	67.78	866
HSA-MIR-6126	99.62	68.09	996
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-4276	99.56	67.66	2514
HSA-MIR-548B-3P	99.38	67.26	1000
HSA-MIR-3911	99.38	66.95	1087
HSA-MIR-888-5P	99.30	70.15	1855
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-4263	99.18	69.25	2236
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-4478	99.07	65.16	2320
HSA-MIR-922	99.02	67.23	1838
HSA-MIR-5701	98.97	69.54	1502
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-6895-3P	98.79	65.69	996
HSA-MIR-4297	98.77	66.95	2013
HSA-MIR-3908	98.75	67.31	1160
HSA-MIR-7977	98.65	66.18	2590
HSA-MIR-7155-5P	98.65	66.14	1290
HSA-MIR-4266	98.53	67.29	1035
HSA-MIR-6838-3P	98.40	65.88	559
HSA-MIR-147A	98.33	66.40	795
HSA-MIR-3929	98.32	65.58	1026
HSA-MIR-599	98.32	66.99	1037
HSA-MIR-4511	98.32	67.97	1500
HSA-MIR-5581-5P	97.91	66.50	965

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 29.3% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 4)

• MXRA7 gene might function as a negative modulator in psoriasis development when propsoriatic factors attack, presumably via expression alteration or redistribution of MXRA7 proteins in keratinocytes. (PMID:29781547)
• [Effect of MXRA7 on the Biological Functions of Acute B Lymphoblastic Leukemia Cell Line REH]. (PMID:36765476)
• Critical role of MXRA7 in differentiation blockade in human acute promyelocytic leukemia cells. (PMID:37419299)
• MXRA7 is involved in monocyte-to-macrophage differentiation. (PMID:38735126)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Matrix-remodeling-associated protein 7 — P84157 (reviewed: P84157)

All UniProt accessions (4): P84157, K7EPS4, K7EQX8, Q6ZR64

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Isoforms (3)

UniProt ID	Names	Canonical?
P84157-1	1	yes
P84157-2	2
P84157-3	3

RefSeq proteins (7): NP_001008528, NP_001008529, NP_001350698, NP_001374205, NP_001374206, NP_001374207, NP_940932* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026622	Mxra7	Family
IPR057534	MXRA7_helical	Domain

Pfam: PF25473

UniProt features (11 total): compositionally biased region 3, splice variant 3, chain 1, transmembrane region 1, sequence conflict 1, region of interest 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P84157-F1	66.29	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 191

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 129 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, VERHAAK_AML_WITH_NPM1_MUTATED_DN, WALLACE_PROSTATE_CANCER_RACE_UP, BENPORATH_ES_WITH_H3K27ME3, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, VICENT_METASTASIS_UP, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_DN, ONKEN_UVEAL_MELANOMA_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_DN, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, GOBP_MEGAKARYOCYTE_DIFFERENTIATION, ROSS_AML_WITH_PML_RARA_FUSION, FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN

GO Biological Process (1): megakaryocyte differentiation (GO:0030219)

GO Molecular Function (0):

GO Cellular Component (2): endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
myeloid cell differentiation	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

394 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MXRA7	MXRA8	Q9BRK3	537
MXRA7	TMEM161B	Q8NDZ6	529
MXRA7	METTL23	Q86XA0	469
MXRA7	SUMF2	Q8NBJ7	463
MXRA7	ATRAID	Q6UW56	436
MXRA7	CLLU1-AS1	Q5K130	399
MXRA7	LRRC71	Q8N4P6	392
MXRA7	WFDC5	Q8TCV5	370
MXRA7	NIPSNAP2	O75323	348
MXRA7	SLC71A2	Q5SR56	345
MXRA7	JMJD6	Q6NYC1	342
MXRA7	DNAJC24	Q6P3W2	337
MXRA7	EEIG2	Q5T8I3	325
MXRA7	SLFN5	Q08AF3	324
MXRA7	CCDC9	Q9Y3X0	323

IntAct

29 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
MXRA7	FAM20C	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
E5	ESYT2	psi-mi:“MI:0914”(association)	0.350
PCDHA12	KLRG2	psi-mi:“MI:0914”(association)	0.350
GUCY1B1	MYCBP2	psi-mi:“MI:0914”(association)	0.350
MAST1	ZSWIM8	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
CCDC47	ESYT2	psi-mi:“MI:0914”(association)	0.350
MAP2K1	BRAF	psi-mi:“MI:0914”(association)	0.350
GRIN3B	DAPK3	psi-mi:“MI:0914”(association)	0.350
GUCY2D	HSP90AA1	psi-mi:“MI:0914”(association)	0.350
GUCY1B1	MXRA7	psi-mi:“MI:0914”(association)	0.350
CLGN	TMEM131L	psi-mi:“MI:0914”(association)	0.350
NIPAL3	ILVBL	psi-mi:“MI:0914”(association)	0.350
SLC30A10	GOLIM4	psi-mi:“MI:0914”(association)	0.350
SLC7A1	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC7A3	ILVBL	psi-mi:“MI:0914”(association)	0.350
CANX	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
sseF	SNAP23	psi-mi:“MI:2364”(proximity)	0.270
CFTR	UBA6	psi-mi:“MI:2364”(proximity)	0.270
MXRA7	MAST2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (106): MXRA7 (Affinity Capture-RNA), MXRA7 (Affinity Capture-RNA), MXRA7 (Affinity Capture-MS), MXRA7 (Affinity Capture-MS), MXRA7 (Proximity Label-MS), MXRA7 (Co-fractionation), MXRA7 (Co-fractionation), MXRA7 (Proximity Label-MS), MXRA7 (Proximity Label-MS), MXRA7 (Proximity Label-MS), MXRA7 (Proximity Label-MS), MXRA7 (Proximity Label-MS), MXRA7 (Proximity Label-MS), MXRA7 (Proximity Label-MS), MXRA7 (Proximity Label-MS)

ESM2 similar proteins: A0A8I5KY20, A2A9T0, A2IDD5, B0BNK9, B8ZZ34, C9JI98, C9JLR9, F5GYI3, O18734, P0CG25, P84157, Q0IIA6, Q0PHV7, Q0X0E2, Q13387, Q1RMK9, Q2M3D2, Q2TAM9, Q3ZCQ3, Q4VA45, Q673H1, Q69YZ2, Q6NS60, Q6P6N5, Q6PJ61, Q7Z6J2, Q80ZJ8, Q810I0, Q86SX3, Q86UD0, Q86XT2, Q8BNN1, Q8IUW3, Q8N4Y2, Q8N6N2, Q8QZV0, Q8R4T5, Q8TF61, Q8VCR9, Q8WXF8

Diamond homologs: P84157, Q9CZH7

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 32 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
protein phosphorylation	5	13.1×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

46 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	37
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1244 predictions. Top by Δscore:

Variant	Effect	Δscore
17:76685066:GCCTA:G	donor_loss	1.0000
17:76685067:CCTAC:C	donor_loss	1.0000
17:76685068:CTACC:C	donor_loss	1.0000
17:76685069:TA:T	donor_loss	1.0000
17:76685070:A:AT	donor_loss	1.0000
17:76685071:C:A	donor_loss	1.0000
17:76685071:CCT:C	donor_gain	1.0000
17:76685166:C:CC	acceptor_gain	1.0000
17:76685166:CTGTG:C	acceptor_loss	1.0000
17:76685167:T:A	acceptor_loss	1.0000
17:76688108:CTCA:C	donor_loss	1.0000
17:76688109:TCACC:T	donor_loss	1.0000
17:76688110:CAC:C	donor_loss	1.0000
17:76688111:ACCGT:A	donor_gain	1.0000
17:76688112:CCGTC:C	donor_gain	1.0000
17:76688173:CTTC:C	acceptor_gain	1.0000
17:76688174:TTC:T	acceptor_gain	1.0000
17:76688177:C:CA	acceptor_loss	1.0000
17:76688177:C:CC	acceptor_gain	1.0000
17:76688178:T:A	acceptor_loss	1.0000
17:76677573:T:TA	donor_gain	0.9900
17:76677574:C:A	donor_gain	0.9900
17:76677599:AGAG:A	donor_gain	0.9900
17:76685070:A:AC	donor_gain	0.9900
17:76685071:C:CC	donor_gain	0.9900
17:76685163:CTC:C	acceptor_gain	0.9900
17:76685168:G:GC	acceptor_gain	0.9900
17:76688111:A:AC	donor_gain	0.9900
17:76688112:C:CC	donor_gain	0.9900
17:76688112:CCGT:C	donor_gain	0.9900

AlphaMissense

1066 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:76685102:A:G	M157T	0.990
17:76710891:G:T	A19D	0.990
17:76685087:A:G	L162P	0.989
17:76685145:A:G	Y143H	0.986
17:76685099:G:A	T158I	0.981
17:76685101:C:A	M157I	0.980
17:76685101:C:G	M157I	0.980
17:76685101:C:T	M157I	0.980
17:76685078:T:A	E165V	0.977
17:76685115:A:C	Y153D	0.977
17:76685115:A:G	Y153H	0.977
17:76710879:G:T	A23D	0.976
17:76685144:T:C	Y143C	0.974
17:76685125:C:A	R149S	0.973
17:76685125:C:G	R149S	0.973
17:76710900:G:T	T16N	0.973
17:76685135:C:T	G146E	0.972
17:76710888:A:T	L20H	0.972
17:76685114:T:G	Y153S	0.971
17:76685145:A:C	Y143D	0.971
17:76710903:G:T	A15D	0.969
17:76685144:T:G	Y143S	0.968
17:76710877:A:G	W24R	0.967
17:76710877:A:T	W24R	0.967
17:76685135:C:A	G146V	0.965
17:76685075:T:G	Q166P	0.964
17:76685114:T:C	Y153C	0.963
17:76685077:C:A	E165D	0.962
17:76685077:C:G	E165D	0.962
17:76685136:C:A	G146W	0.962

dbSNP variants (sampled 300 via entrez): RS1000026299 (17:76683916 G>A), RS1000028392 (17:76674393 G>A), RS1000087203 (17:76688961 C>A,T), RS1000098488 (17:76674235 C>G), RS1000120208 (17:76710735 G>A), RS1000182846 (17:76710577 A>G,T), RS1000287212 (17:76680246 T>A), RS1000340616 (17:76699480 C>T), RS1000394510 (17:76699151 T>C), RS1000518388 (17:76710838 G>A,T), RS1000706221 (17:76697998 G>A), RS1000840076 (17:76676190 G>A), RS1000919836 (17:76706764 G>T), RS1000969520 (17:76702998 G>A), RS1001032704 (17:76675790 C>G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST002071_2	Retinal arteriolar caliber	2.000000e-10
GCST006585_2387	Blood protein levels	1.000000e-36
GCST006629_13	Pulse pressure	8.000000e-12
GCST007269_166	Pulse pressure	3.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004731	eye measurement
EFO:0005763	pulse pressure measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

55 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol F	decreases expression, increases expression, affects cotreatment	3
trichostatin A	affects cotreatment, decreases expression, affects expression	3
bisphenol A	affects cotreatment, increases methylation, increases expression	2
entinostat	decreases expression, increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, decreases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
Doxorubicin	affects expression, decreases expression	2
Valproic Acid	increases expression	2
Cyclosporine	increases expression	2
Particulate Matter	affects cotreatment, decreases expression, increases abundance	2
FR900359	affects phosphorylation	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
coumarin	affects phosphorylation	1
beta-methylcholine	affects expression	1
2,3-dimethoxy-1,4-naphthoquinone	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
bisphenol B	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	increases expression	1
NSC 689534	affects binding, decreases expression	1
bisphenol AF	increases expression	1
Temozolomide	decreases expression	1
Zoledronic Acid	increases expression	1
Arsenic Trioxide	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.